Antares Pharma (NASDAQ:ATRS) and Becton Dickinson and (NYSE:BDX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, analyst recommendations and risk.

Dividends

Becton Dickinson and pays an annual dividend of $3.08 per share and has a dividend yield of 1.2%. Antares Pharma does not pay a dividend. Becton Dickinson and pays out 26.4% of its earnings in the form of a dividend.

Institutional and Insider Ownership

38.6% of Antares Pharma shares are owned by institutional investors. Comparatively, 84.7% of Becton Dickinson and shares are owned by institutional investors. 5.5% of Antares Pharma shares are owned by insiders. Comparatively, 0.1% of Becton Dickinson and shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Antares Pharma has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500. Comparatively, Becton Dickinson and has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Antares Pharma and Becton Dickinson and, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Antares Pharma 0 0 2 1 3.33
Becton Dickinson and 0 3 6 1 2.80

Antares Pharma presently has a consensus target price of $4.05, indicating a potential downside of 20.03%. Becton Dickinson and has a consensus target price of $268.30, indicating a potential upside of 4.92%. Given Becton Dickinson and’s higher possible upside, analysts plainly believe Becton Dickinson and is more favorable than Antares Pharma.

Profitability

This table compares Antares Pharma and Becton Dickinson and’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Antares Pharma -0.56% -1.40% -0.56%
Becton Dickinson and 6.84% 15.52% 6.32%

Earnings and Valuation

This table compares Antares Pharma and Becton Dickinson and’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Antares Pharma $63.55 million 13.00 -$6.51 million ($0.04) -126.50
Becton Dickinson and $17.29 billion 4.00 $1.23 billion $11.68 21.89

Becton Dickinson and has higher revenue and earnings than Antares Pharma. Antares Pharma is trading at a lower price-to-earnings ratio than Becton Dickinson and, indicating that it is currently the more affordable of the two stocks.

Summary

Becton Dickinson and beats Antares Pharma on 12 of the 16 factors compared between the two stocks.

Antares Pharma Company Profile

Antares Pharma, Inc. focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults. Its injection products also comprise Epinephrine Injection USP for treating Anaphylaxis; Makena auto injectors to reduce the risk of preterm birth in women pregnant with a single baby; ZOMAJET and Twin-Jector EZ II Needle-free Injectors to administer human growth hormone for patients with growth retardation. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; and QuickShot auto injectors. It has strategic alliances with Teva Pharmaceutical Industries, Ltd., AMAG Pharmaceuticals, Inc., and Pfizer Inc. The company was founded in 1978 and is headquartered in Ewing, New Jersey.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, monoclonal antibodies and kits, reagent systems, bench-side solutions, and molecular indexing and next-generation sequencing sample preparation products, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, thoracic and abdominal drainage, and surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.